Recent studies identify ARRB1 as a key modulator in HBV-associated HCC, highlighting its therapeutic potential due to its role in autophagy and the CDKN1B-CDK2-CCNE1-E2F1 signaling pathway (Lei et al., 2021). Here, E2F1 is linked to hepatocellular carcinoma.